13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)

Page 2 of 6 – SEC Filing

CUSIP No. 253031108

1

Names of Reporting Persons.

RA Capital Management, LLC

2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨
(b) ¨
3 SEC Use Only
4

Source of Funds (See Instructions):

AF

5

Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):

¨

6 Citizenship or Place of Organization.     Massachusetts

Number

of Shares

Beneficially

Owned by

Each

Reporting

Person With

7
Sole Voting Power     0
8
Shared Voting Power      3,933,489
9
Sole Dispositive Power     0
10
Shared Dispositive Power  3,933,489
11

Aggregate Amount Beneficially Owned by
Each Reporting Person

3,933,489

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)     ¨
13

Percent of Class Represented by Amount
in Row (11)

7.6%1

14

Type of Reporting Person (See Instructions)

IA, OO (Limited Liability Company)

 

 

1
Represents 3,933,489 shares of the common stock (the “Common Stock”) of Dicerna Pharmaceuticals, Inc.
(the “Issuer”) which constitutes approximately 7.6% of the class outstanding. The percentage calculation assumes that
there are currently 51,766,999 outstanding shares of the Common Stock of the Issuer, based on the Issuer’s Form 10-K as
filed with the Securities and Exchange Commission (“SEC”) on March 8, 2018. 

Follow Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)